TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02052947

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-DaTscan
Description: * Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~* LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted).
Study: NCT03905005

Intervention type: PROCEDURE
Intervention: Mandibular reconstruction with free tissue transfer.
Description: Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).

Intervention type: PROCEDURE
Intervention: Mandibular reconstruction with free tissue transfer.
Description: Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
Study: NCT00528905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD3480
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: oral capsule
Study: NCT01546766

Intervention type: DEVICE
Intervention: Pupillometry testing.
Study: NCT03127098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: ETBX-011 immunization was administered by subcutaneous (SC) injection.
Study: NCT01546766

Intervention type: DEVICE
Intervention: Pupillometry testing.

Intervention type: DEVICE
Intervention: Pupillometry testing.
Study: NCT00189956

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMVAMUNE (MVA-BN)
Description: Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMVAMUNE (MVA-BN)
Description: Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
Study: NCT03127098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: ALT-803 was administered by SC injection.
Study: NCT00189956

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMVAMUNE (MVA-BN)
Description: Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
Study: NCT02256293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
Description: The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
Study: NCT04471272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA using gradual RF energy delivery mode with Octopus electrodes
Description: RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
Study: NCT02589808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full TTE
Description: Full transthoracic echocardiogram, with Doppler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Vscan
Description: Handheld echo.
Study: NCT03686033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.
Study: NCT03633877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DuraporeTM and Hy-Tape®
Description: Medical tapes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DuraporeTM and Hy-Tape®
Description: Medical tapes
Study: NCT03104816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen IV Soln 10 MG/ML

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study: NCT03686033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2082-matched placebo tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.
Study: NCT03104816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study: NCT03686033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Participants will receive E2082 tablets orally.
Study: NCT01045161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
Study: NCT03678844

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Taekwondo practice
Description: The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
Study: NCT02794337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
Study: NCT03678844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taekwondo practice
Description: The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
Study: NCT04512092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training for Caregivers
Description: CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
Study: NCT04821401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rejuvant
Description: Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rejuvant
Description: Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
Study: NCT00830206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral Suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax®
Description: Oral Suspension
Study: NCT03744364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 25 mcg
Description: To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 10mg
Description: To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
Study: NCT03412357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurectomy/decortication
Description: VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indwelling pleural catheter
Description: A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
Study: NCT04455230

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FLT190
Description: FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
Study: NCT01748630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study: NCT00450190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saizen® E-Device
Description: Saizen® (recombinant human growth hormone \[r-hGH\]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
Study: NCT02133105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Study: NCT02918877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Volatile Anesthetic
Study: NCT02794337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
Study: NCT02918877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous Anesthetic
Study: NCT00518830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-component intervention
Description: The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
Study: NCT02760368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study: NCT03037723

Intervention type: OTHER
Group type: OTHER
Intervention: CT simulation
Study: NCT03033147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet
Description: 2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: placebo 30 minutes before root canal treatment
Study: NCT05711303

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Superba Boost
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Superba Boost
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
Study: NCT02119676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
Study: NCT00745108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tibolone
Description: oral 1.25 mg tablet, once daily, for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Description: oral 2.5 mg tablet, once daily, for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CE/MPA
Description: oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
Study: NCT04752761

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Extrambulatory digital PROMs detection
Description: An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
Study: NCT04779502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oregawash
Description: mouthwash containing oregano essential oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corsodyl
Description: 0.2% chlorhexidine mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: distilled water
Study: NCT00267735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Computerized Decision Aid on Childbirth
Study: NCT02770807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EryDex Low dose DSP
Description: EDS-EP dose range of \~5-10 mg DSP/infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EryDex High dose DSP
Description: EDS-EP dose range of \~14-22 mg DSP/infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pooled Placebo
Description: EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
Study: NCT03906253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Study: NCT00331435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular photodynamic therapy with verteporfin
Description: Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ocular photodynamic therapy with verteporfin
Description: Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
Study: NCT01871792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
Study: NCT00426348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan (80-160mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (80-160mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol (750mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02000609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 NEXThaler 800/48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 NEXThaler 200/12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF 1535 NEXThaler PLACEBO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 pMDI 200/12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535 pMDI 800/48
Study: NCT02525289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed Rotation Group
Description: Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthostatic Group
Description: Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.